Mechanism:As a "dual agonist, " it mimics two hormones (GIP and GLP-1) to manage blood sugar and increase fullness.
Weight Loss Efficacy:Clinical trials, such as Surmount-5, showed tirzepatide (Mounjaro/Zepbound) resulted in approximately 20.2% weight loss, compared to 13.7% for semaglutide.
Administration:It is a self-administered, once-weekly injection in the stomach, thigh, or upper arm.
Dosage:Starts at 2.5mg, with 4-week intervals increasing up to a 15mg maximum.
Side Effects:Common side effects include nausea, diarrhea, vomiting, constipation, and abdominal pain.